Integra LifeSciences (IART) reported $402.06 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 5.6%. EPS of $0.54 for the same period compares to $0.41 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $414.8 million, representing a surprise of -3.07%. The company delivered an EPS surprise of +25.58%, with the consensus EPS estimate being $0.43.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Integra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Organic Revenue Growth: 5% versus the four-analyst average estimate of 8.5%.
- Revenue- Codman Specialty Surgical- Total: $292.58 million versus $300.46 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +8.1% change.
- Revenue- Tissue Technologies- Total: $109.48 million versus $114.4 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -0.5% change.
- Revenue- Tissue Technologies- Wound Reconstruction and Care: $83.99 million compared to the $84.83 million average estimate based on two analysts. The reported number represents a change of +4.4% year over year.
- Revenue- Tissue Technologies- Private Label: $25.49 million compared to the $29.58 million average estimate based on two analysts. The reported number represents a change of -13.9% year over year.
View all Key Company Metrics for Integra here>>>
Shares of Integra have returned +4.8% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
